broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K13049116-001-04-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.331359 | 0.140448 | 0.017836 | 1 | 0.642085 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000997 |
BRD-K13390322-001-06-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 2.44235 | 5.303515 | 0.885161 | 1 | 0.556072 | null | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000997 |
BRD-K13514097-001-04-6 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.364723 | -0.037658 | -0.00351 | 1 | 23,944.222512 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000997 |
BRD-K13662825-001-07-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.206959 | 23.963144 | 0.545514 | 0.739585 | 0.103374 | 0.105706 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000997 |
BRD-K14109347-001-03-4 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.156351 | 4.82493 | 0.741017 | 0.960237 | 6.484089 | 7.008123 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000997 |
BRD-K15179879-001-03-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.138947 | 19.119764 | 0.138284 | 0.661331 | 0.219932 | 0.223711 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000997 |
BRD-K15600710-066-05-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.199625 | 7.813152 | 0.749157 | 0.721692 | 0.336139 | 0.35879 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000997 |
BRD-K16730910-001-10-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.880663 | -2.734525 | 0.04964 | 0.90593 | 1.282934 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000997 |
BRD-K17555800-003-02-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.811508 | -4.837733 | 0.191666 | 0.927532 | 0.025451 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000997 |
BRD-K17610631-001-03-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.399296 | 4.058622 | 0.766793 | 0.805464 | 0.41806 | 0.620446 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000997 |
BRD-K17743125-001-08-4 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.166065 | -0.01701 | -0.022053 | 1 | 0.017225 | null | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000997 |
BRD-K17894950-001-14-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | -0.943558 | 0.345964 | -0.028164 | 0.984635 | 311,297.524423 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000997 |
BRD-K18961567-001-01-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.016882 | 0.215009 | -0.014534 | 1 | 0.031505 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000997 |
BRD-K19540840-001-09-4 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.879715 | 0.331982 | -0.011283 | 0.904983 | 0.000706 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000997 |
BRD-K19687926-001-04-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.155583 | 5.567674 | 0.619416 | 0.960618 | 6.456245 | 6.903248 | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000997 |
BRD-K19796430-001-05-6 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.000667 | 0.000078 | -0.069674 | 1 | 1,235.646587 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000997 |
BRD-K22064724-001-01-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.112007 | 2.911497 | 0.834561 | 0.660979 | 0.245987 | 0.268376 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000997 |
BRD-K22822991-001-02-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.929578 | 1.138774 | 0.020983 | 0.954933 | 0.019765 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000997 |
BRD-K23228615-001-02-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.361583 | 2.618877 | 0.571701 | 0.914802 | 2.774704 | 4.531117 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000997 |
BRD-K23984367-001-07-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 3.21902 | 0.508767 | 0.09124 | 1 | 2,212.709229 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000997 |
BRD-K26026438-001-01-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.505996 | 1.951993 | 0.498744 | 0.850046 | 0.526443 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000997 |
BRD-K26657438-001-15-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.119764 | 0.331453 | -0.07433 | 1 | 0.010728 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000997 |
BRD-K29905972-001-06-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.875376 | 0.255409 | -0.048643 | 0.920325 | 0.006328 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000997 |
BRD-K30577245-001-05-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.198348 | 5.081225 | 0.183052 | 0.894415 | 0.174124 | 0.192331 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000997 |
BRD-K31698212-001-02-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.233366 | -0.002902 | -0.0044 | 1 | 0.048463 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000997 |
BRD-K31928526-001-02-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.388348 | 0.303768 | 0.034064 | 1 | 0.534254 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000997 |
BRD-K33379087-001-07-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.168706 | 1.029771 | 0.816208 | 0.727084 | 0.428511 | 0.639077 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000997 |
BRD-K33610132-001-02-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.829397 | 0.147013 | -0.207324 | 1 | 911.024062 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000997 |
BRD-K33622447-066-01-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.504629 | 4.476399 | 0.385079 | 0.918479 | 2.025287 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000997 |
BRD-K35520305-001-16-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.913382 | -1.956405 | 0.044128 | 0.94701 | 0.231151 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000997 |
BRD-K36627727-001-05-4 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 32.662067 | 0.539271 | -0.000253 | 1 | 503,438,818,470.1746 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000997 |
BRD-K36788280-001-01-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.385005 | 1.57041 | 0.480752 | 1 | 0.803603 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000997 |
BRD-K37379014-001-02-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.318015 | 5.495937 | 0.550754 | 0.893981 | 0.034512 | 0.04148 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000997 |
BRD-K38332599-001-01-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.023057 | -0.076254 | -0.056906 | 1 | 509,223,547,348.2109 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000997 |
BRD-K38527262-300-01-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.178715 | 1.904123 | 0.657959 | 0.813338 | 1.022376 | 1.289689 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000997 |
BRD-K38852836-001-02-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.377463 | 3.74336 | 0.58439 | 0.719367 | 0.031525 | 0.045898 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000997 |
BRD-K39974922-001-04-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.945954 | 1.570758 | 0.046388 | 0.987512 | 1.082517 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000997 |
BRD-K41859756-001-06-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.509253 | 7.41591 | 0.485488 | 0.831338 | 0.089107 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000997 |
BRD-K42495768-001-01-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.106399 | 0.024932 | -0.023754 | 1 | 0.003463 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000997 |
BRD-K42805893-001-04-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.03869 | 1.690601 | -0.006882 | 1 | 0.088665 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000997 |
BRD-K42828737-001-03-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.271452 | 0.617295 | 0.078099 | 1 | 0.495594 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000997 |
BRD-K42898655-001-01-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.113808 | -0.066289 | -0.045282 | 1 | 4.318702 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000997 |
BRD-K43389675-001-02-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.14016 | 1.817812 | 0.262893 | 0.762353 | 0.687003 | 0.823273 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000997 |
BRD-K44227013-001-06-4 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.173451 | 7.036472 | 0.481356 | 0.962457 | 6.477466 | 6.881766 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000997 |
BRD-K44408410-001-17-6 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.170855 | 1.999217 | 0.656353 | 0.905005 | 3.483606 | 4.293904 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000997 |
BRD-K44827188-001-06-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.718114 | 0.57776 | 0.084745 | 0.849836 | 0.054563 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000997 |
BRD-K46386702-001-02-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.90118 | -1.768421 | 0.006608 | 0.939577 | 0.230503 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000997 |
BRD-K49328571-001-15-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 2.188729 | 0.534534 | 0.508728 | 1 | 1.428851 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000997 |
BRD-K49350383-001-14-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.321532 | 3.918562 | 0.329577 | 0.957656 | 5.594979 | 7.277384 | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000997 |
BRD-K50010139-001-01-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.991594 | 0.12784 | -0.020187 | 0.995041 | 0.004148 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000997 |
BRD-K50168500-001-07-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.426038 | 2.460259 | 0.10201 | 1 | 0.549787 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000997 |
BRD-K51313569-001-07-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.145413 | 0.402687 | 0.005983 | 1 | 0.001667 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000997 |
BRD-K51791723-003-01-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.145701 | 5.461456 | 0.668861 | 0.854458 | 1.914176 | 2.038793 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000997 |
BRD-K51967704-001-03-6 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.363248 | 3.196238 | 0.75259 | 0.742889 | 0.198692 | 0.298085 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000997 |
BRD-K52313696-001-12-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.001408 | -0.568285 | -0.168355 | 1 | 0.273024 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000997 |
BRD-K53414658-001-08-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.036467 | -0.018577 | -0.043577 | 1 | 0.343717 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000997 |
BRD-K53972329-001-07-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.337225 | 2.493825 | 0.089931 | 1 | 0.069602 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000997 |
BRD-K54256913-001-08-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.011763 | -3.746523 | -0.000062 | 1 | 0.065502 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000997 |
BRD-K54955827-001-02-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.318258 | 4.487372 | 0.544372 | 0.89768 | 2.331163 | 2.920867 | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000997 |
BRD-K54997624-001-06-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.005536 | -0.159649 | -0.010047 | 1 | 0.308377 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000997 |
BRD-K55187425-236-05-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.187769 | 2.187086 | 0.756854 | 0.553301 | 0.048091 | 0.059644 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000997 |
BRD-K56343971-001-14-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.02922 | -0.09821 | -0.004003 | 1 | 0.014709 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000997 |
BRD-K56981171-001-02-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.037062 | -0.322752 | -0.153345 | 1 | 11.47011 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000997 |
BRD-K57080016-001-15-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.95889 | 0.671929 | 0.763192 | 1 | 0.3615 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000997 |
BRD-K57169635-001-04-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.106836 | 4.512581 | 0.656029 | 0.903631 | 3.516488 | 3.70895 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000997 |
BRD-K58435339-001-03-0 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.397031 | 0.338985 | 0.460503 | 0.693887 | 0.069957 | 7.401114 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000997 |
BRD-K58529924-001-01-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.784016 | 1.896302 | 0.044554 | 0.919128 | 0.280143 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000997 |
BRD-K58550667-001-08-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.006195 | 0.403305 | 0.631982 | 0.661865 | 0.040478 | 0.041749 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000997 |
BRD-K59317601-001-05-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.449071 | 1.050204 | 0.635581 | 0.808802 | 0.353993 | 3.115819 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000997 |
BRD-K59369769-001-22-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.515058 | 3.889702 | 0.60543 | 1 | 0.095011 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000997 |
BRD-K60866521-001-07-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.143323 | -0.484685 | 0.012477 | 1 | 0.010925 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000997 |
BRD-K60997853-001-02-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.856081 | 0.219619 | 0.008484 | 0.912306 | 0.008579 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000997 |
BRD-K61192372-001-08-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.760245 | -0.36343 | 0.132255 | 0.920575 | 0.007167 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000997 |
BRD-K62196610-001-01-6 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.98223 | 2.115791 | -0.012294 | 0.986359 | 0.005794 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000997 |
BRD-K62200014-003-10-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.915986 | -0.099804 | -0.05862 | 0.937794 | 3,428.111084 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000997 |
BRD-K62391742-001-09-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 4.254113 | 1.292268 | 0.339651 | 1 | 36.942747 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000997 |
BRD-K62627508-001-01-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.791486 | 0.75691 | 0.673814 | 1 | 0.671283 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000997 |
BRD-K63712959-001-01-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.173574 | 2.361266 | 0.100395 | 1 | 0.027846 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000997 |
BRD-K64052750-001-22-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.779481 | 0.266419 | -0.014576 | 0.88866 | 0.071844 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000997 |
BRD-K64881305-001-03-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.470154 | 5.780911 | 0.193601 | 0.750391 | 0.103391 | 0.168358 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000997 |
BRD-K66175015-001-12-4 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.184658 | 10.473634 | 0.429255 | 0.96765 | 6.815787 | 7.122449 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000997 |
BRD-K67844266-003-01-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.664893 | 6.20154 | 0.36551 | 0.918403 | 0.94135 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000997 |
BRD-K69001009-001-02-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.89551 | 0.549392 | 0.056131 | 0.964647 | 0.492783 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000997 |
BRD-K69694239-001-02-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.154158 | 4.489366 | 0.87875 | 0.748089 | 0.555615 | 0.603155 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000997 |
BRD-K69776681-001-03-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.726598 | -4.376188 | -0.002586 | 0.960575 | 0.002471 | null | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000997 |
BRD-K70301465-001-05-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.022558 | 0.210721 | -0.062656 | 1 | 0.001436 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000997 |
BRD-K70401845-001-15-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.287868 | -0.153537 | -0.05741 | 1 | 0.122826 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000997 |
BRD-K73838513-003-05-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.475888 | 2.794607 | 0.36979 | 0.92432 | 2.480503 | 7.340273 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000997 |
BRD-K74514084-003-09-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.155838 | 0.779036 | -0.034485 | 1 | 0.050543 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000997 |
BRD-K75009076-001-02-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.228888 | -0.724026 | -0.049301 | 0.986613 | 0.000036 | null | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000997 |
BRD-K76210423-001-01-6 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.607887 | 1.0283 | -0.015256 | 0.996406 | 97.878225 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000997 |
BRD-K76674262-001-03-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.281583 | -0.083897 | -0.02573 | 1 | 0.000225 | null | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000997 |
BRD-K76908866-001-07-6 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.017869 | -0.31537 | -0.11255 | 1 | 0.030211 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000997 |
BRD-K77625799-001-07-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.099885 | 0.136511 | -0.008964 | 1 | 0.004666 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000997 |
BRD-K78431006-001-15-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.839357 | -3.45569 | 0.050473 | 0.905802 | 0.180605 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000997 |
BRD-K79254416-001-21-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.447714 | 0.695035 | 0.447769 | 1 | 0.065464 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000997 |
BRD-K81418486-001-44-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.662186 | 0.395077 | -0.00871 | 1 | 94.140902 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000997 |
BRD-K81473043-001-19-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.966498 | -0.173069 | -0.062504 | 0.978343 | 0.194018 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000997 |
BRD-K82135108-001-04-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.327491 | -0.758265 | -0.07493 | 1 | 0.001117 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000997 |
BRD-K82746043-001-19-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.403698 | 1.701911 | 0.111244 | 1 | 0.011589 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000997 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.